scholarly journals Cough, airway inflammation, and mild asthma exacerbation

2002 ◽  
Vol 86 (4) ◽  
pp. 270-275 ◽  
Author(s):  
A B Chang
2019 ◽  
Vol 29 (4) ◽  
pp. 419-427
Author(s):  
S. N. Avdeev ◽  
Z. R. Aisanov ◽  
A. S. Belevskiy ◽  
A. V. Emelyanov ◽  
N. P. Knyazheskaya ◽  
...  

According to the modern concepts, asthma is a heterogeneous disease characterized by chronic airway inflammation and respiratory symptoms, which vary in time and intensity and manifest together with variable obstruction of the airways. Asthma is responsible for the deterioration of health status and quality of life in approximately 339 million of adult patients and children worldwide. Despite the fact that asthma is a chronic inflammatory disease, patients with asthma generally inadequately receive anti-inflammatory therapy in real clinical practice and rely on short-acting beta2-agonists (SABA) too much; this can “mimic” worsening of asthma symptoms. SABA monotherapy “on demand” does not affect chronic airway inflammation, underlying asthma occurrence and progression. As a result, such patients still have the risk of asthma exacerbation and disease progression. Therefore, the need of a new therapeutic strategy for patients with milder asthma (steps 1 and 2), which would provide anti-inflammatory treatment considering the low adherence to the regular maintenance therapy and high dependency on SABA, is obvious. Such approach has become available after the SYGMA (SYmbicort® Given as needed in Mild Asthma) trial was completed. According to the results of this trial, budesonide/formoterol 160/4.5 µg/dose as needed was superior to as needed SABA in better asthma control and decrease in severe asthma exacerbation rate by 64% (p < 0.001). Results of SYGMA 1 and 2 trials also demonstrated that budesonide/formoterol 160/4.5 µg/dose as needed was noninferior compared to regular treatment with budesonide in preventing severe asthma exacerbations while the cumulative dose of budesonide was reduced by ≥75%. 


2021 ◽  
Vol 11 (6) ◽  
Author(s):  
Anet Laanesoo ◽  
Egon Urgard ◽  
Kapilraj Periyasamy ◽  
Martti Laan ◽  
Yury A. Bochkov ◽  
...  

2012 ◽  
Vol 2012 ◽  
pp. 1-14 ◽  
Author(s):  
Mutsuo Yamaya

Infection with respiratory viruses, including rhinoviruses, influenza virus, and respiratory syncytial virus, exacerbates asthma, which is associated with processes such as airway inflammation, airway hyperresponsiveness, and mucus hypersecretion. In patients with viral infections and with infection-induced asthma exacerbation, inflammatory mediators and substances, including interleukins (ILs), leukotrienes and histamine, have been identified in the airway secretions, serum, plasma, and urine. Viral infections induce an accumulation of inflammatory cells in the airway mucosa and submucosa, including neutrophils, lymphocytes and eosinophils. Viral infections also enhance the production of inflammatory mediators and substances in airway epithelial cells, mast cells, and other inflammatory cells, such as IL-1, IL-6, IL-8, GM-CSF, RANTES, histamine, and intercellular adhesion molecule-1. Viral infections affect the barrier function of the airway epithelial cells and vascular endothelial cells. Recent reports have demonstrated augmented viral production mediated by an impaired interferon response in the airway epithelial cells of asthma patients. Several drugs used for the treatment of bronchial asthma reduce viral and pro-inflammatory cytokine release from airway epithelial cells infected with viruses. Here, I review the literature on the pathogenesis of the viral infection-induced exacerbation of asthma and on the modulation of viral infection-induced airway inflammation.


2003 ◽  
Vol 111 (5) ◽  
pp. 958-966 ◽  
Author(s):  
Yasuyuki Sano ◽  
Naohito Suzuki ◽  
Hirokazu Yamada ◽  
Yasuo To ◽  
Chuhei Ogawa ◽  
...  

2003 ◽  
Vol 111 (1) ◽  
pp. 0197-0198 ◽  
Author(s):  
Jun Tamaoki ◽  
Kiyoshi Takeyama ◽  
Kazutetsu Aoshiba ◽  
Junko Nakata ◽  
Kazuyuki Nishimura ◽  
...  

2010 ◽  
Vol 45 (2) ◽  
pp. 174-181 ◽  
Author(s):  
James L. Puckett ◽  
Richard W.E. Taylor ◽  
Szu-Yun Leu ◽  
Olga L. Guijon ◽  
Anna S. Aledia ◽  
...  

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Jun Hanashiro ◽  
Yasunori Muraosa ◽  
Takahito Toyotome ◽  
Koichi Hirose ◽  
Akira Watanabe ◽  
...  

AbstractSchizophyllum commune is a ubiquitous basidiomycetous fungus typically found across the world, which has been detected in indoor and outdoor air. Some studies indicated that sensitization to S. commune is correlated with asthma severity in patients. Patients with chronic severe or acute fatal asthma have neutrophil-dominant airway inflammation. We hypothesized that S. commune can exacerbate asthma. To test this hypothesis, we evaluated the direct immunomodulatory activities of S. commune in allergic airway inflammation induced by non-fungal sensitization. Ovalbumin (OVA)-induced asthma model mice were generated using wild-type (WT) and Il-17a−/−Il-17f−/− mice that were intratracheally exposed to S. commune, then immune responses in the lungs were assessed after 24 h. Intratracheal administration of S. commune in OVA-induced asthma model mice enhanced neutrophilic airway inflammation, increased the mRNA expression of CXCL1 and CXCL2 in the lungs, and provoked IL-17A, and IL-17F production in BAL fluid. In addition, neutrophilic airway inflammation was significantly inhibited in Il-17a−/−Il-17f−/− mice compared with those found in WT mice. We demonstrated that S. commune induces neutrophilic airway inflammation in OVA-induced asthma model mice, and IL-17A and IL-17F had central roles in this activity. As S. commune inhabits the general environment, including indoor and outdoor air, our results suggested that S. commune is a causative agent of asthma exacerbation. This study has provided clues regarding the mechanisms behind fungi and asthma exacerbation.


2005 ◽  
Vol 115 (2) ◽  
pp. S175
Author(s):  
P. Prince ◽  
L.P. Boulet ◽  
H. Turcotte ◽  
P. Bégin ◽  
C. Lemière ◽  
...  

Author(s):  
Michael Shapiro ◽  
Konstantin Zubkov ◽  
Yossi Rosman ◽  
Regev Landau

<b><i>Background:</i></b> The effects of high-risk environment on young adults with mild asthma were never fully tested in practice, as most high-risk occupations do not welcome them. This study examines the effect of combat training on asthma worsening in the Israeli Defense Forces. <b><i>Methods:</i></b> Persons with asthma in remission and mild intermittent asthma who underwent combat training between 2014 and 2017 were compared in terms of disease worsening to their counterparts performing clerical duties during a follow-up of 8 months. Among combat trainees, exposure to known triggers for asthma exacerbation and health status on enlistment were assessed as risk factors for asthma exacerbation. <b><i>Results:</i></b> Asthma worsening among persons with asthma in remission was twice as common among those who are undergoing training compared to persons performing clerical duties. This difference was smaller among mild intermittent asthmatics. For both asthma severities, rates of asthma exacerbation requiring emergency room treatment were several times higher among the training group. Among individuals undergoing training, mild intermittent asthma was a significant risk factor for asthma worsening compared to asthma in remission (OR 1.99 [1.44–2.75]) while age (OR 0.67 [0.53–0.85]) and immigration to Israel (OR 0.55 [0.31–0.95]) were significant protective factors. <b><i>Interpretation:</i></b> Young adults with mild asthma are at significant risk for severe exacerbations when exposed to high-risk environment even among individuals who have long been symptom free. No single risk factor was found to have an independent effect suggesting a synergistic mechanism that is harder to mitigate.


Thorax ◽  
1999 ◽  
Vol 54 (2) ◽  
pp. 108-114 ◽  
Author(s):  
A. Jatakanon ◽  
S. Kharitonov ◽  
S. Lim ◽  
P. J Barnes

Sign in / Sign up

Export Citation Format

Share Document